Company Encyclopedia
View More
name
JIANMIN GROUP
600976.SH
Jianmin Pharmaceutical Group Co.,Ltd. manufactures and sells medicines in China. It provides medicines and pediatric drugs under the Jianmin, Longmu, and Yekaitai brand name. The company provides OTC, medical, and general health products, as well as consultation service.
3.157 T
600976.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking135/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE13.11%B
    • Profit Margin10.28%B
    • Gross Margin58.77%B
  • Growth ScoreD
    • Revenue YoY-20.15%E
    • Net Profit YoY-23.75%D
    • Total Assets YoY3.14%C
    • Net Assets YoY8.06%B
  • Cash ScoreD
    • Cash Flow Margin973.21%B
    • OCF YoY-20.15%E
  • Operating ScoreB
    • Turnover0.74B
  • Debt ScoreB
    • Gearing Ratio40.05%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    JIANMIN GROUP released its performance for the first three quarters, with a net profit attributable to the parent company of 286 million yuan, a year-on-year decrease of 11.16%

    According to the Zhitong Finance APP, JIANMIN GROUP disclosed its third-quarter report for 2025. The company achieved revenue of 2.552 billion yuan in the first three quarters, a year-on-year decrease of 11.43%; the net profit attributable to shareholders of the listed company was 286 million yuan, a year-on-year decrease of 11.16%; the net profit excluding non-recurring gains and losses was 256 million yuan, a year-on-year decrease of 5.58%; the basic earnings per share were 1.88 yuan

    Zhitong·
    SH
    600976
    -0.24%
    Zhitong·
    SH
    600976
    -0.24%

    JIANMIN GROUP: Furosemide oral solution approved for market launch

    According to the Zhitong Finance APP, JIANMIN GROUP announced that the oral solution of Furosemide developed by the company has been approved for marketing by the National Medical Products Administration. The approval of the chemical generic drug oral solution of Furosemide will further enrich the company's product line, enhance the company's core competitiveness, and have a positive impact on the company's future development

    Zhitong·
    SH
    600976
    -0.24%
    Zhitong·
    SH
    600976
    -0.24%

    JIANMIN GROUP: Net profit of 221 million yuan in the first half of 2025, a year-on-year decrease of 7.83%

    JIANMIN GROUP announced that in the first half of 2025, operating revenue was 1.805 billion yuan, a year-on-year decrease of 10.20%. Net profit was 221 million yuan, a year-on-year decrease of 7.83%

    Zhitong·
    SH
    600976
    -0.24%
    Zhitong·
    SH
    600976
    -0.24%

    JIANMIN GROUP: Clinical trial for BiYuan TongQiao granules drug approved

    On the evening of August 14th, JIANMIN GROUP announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the Nasal Congestion Relief Granules, which is indicated for acute sinusitis

    Zhitong·
    SH
    600976
    -0.24%
    Zhitong·
    SH
    600976
    -0.24%

    JIANMIN GROUP: Yuan Pingdong serves as the chairman of the company

    On the evening of July 30th, JIANMIN GROUP announced that the board of directors elected Yuan Pingdong as the chairman of the 11th board of directors. The board of directors authorized the board office to make adaptive revisions to internal systems, such as deleting the supervisory board/supervisors, the audit committee of the board of directors performing supervisory functions, and revising "shareholders' meeting" to "shareholders' association," subject to the approval of the board secretary

    Zhitong·
    SH
    600976
    -0.24%
    Zhitong·
    SH
    600976
    -0.24%
    © 2025 Longbridge｜Disclaimer